Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.37 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.37 |
| ▸ | KLK1 | P06870 | 1/20 | 0.36 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.36 |
| ▸ | AGTR1 | P30556 | 2/20 | 0.34 |
| ▸ | AGTR2 | P50052 | 2/20 | 0.34 |
| ▸ | PPARG | P37231 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL652416 | 0.94 | ADRA1D (0.37) | TSHRHSP90AA1HSP90AB1AGTR1PPARG | |
| SCHEMBL14572934 | 0.90 | PDK1 (0.40) | TSHRHSP90AA1HSP90AB1KLK1LTB4R2 | |
| SCHEMBL650483 | 0.88 | AGTR1 (0.35) | AGTR1AGTR2PPARG | |
| SCHEMBL652197 | 0.82 | AGTR1 (0.35) | AGTR1AGTR2 | |
| SCHEMBL5181418 | 0.82 | SMPD1 (0.40) | TSHRHSP90AA1ALDH1A1RXFP1L3MBTL1 | |
| SCHEMBL648253 | 0.81 | TSHR (0.41) | TSHRKLK1LTB4R2PPARGRXFP1 | |
| SCHEMBL652764 | 0.80 | TRPA1 (0.38) | TSHRALDH1A1RXFP1L3MBTL1 | |
| SCHEMBL648120 | 0.79 | SMPD1 (0.38) | ALDH1A1RXFP1L3MBTL1 | |
| SCHEMBL650278 | 0.79 | C5AR1 (0.40) | TSHRLTB4R2AGTR1PPARGL3MBTL1 | |
| SCHEMBL648586 | 0.78 | C5AR1 (0.39) | TSHRLTB4R2PPARGRXFP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8119665-B2 | Aryl imidazoles and related compounds as C5a receptor modulators | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2012-02-21 | — | — | US | disclosed |
| US-8119665-B2 | Aryl imidazoles and related compounds as C5a receptor modulators | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2012-02-21 | — | — | US | disclosed |
| US-8119319-B2 | Method for producing positive charging toner | BROTHER KOGYO KABUSHIKI KAISHA (JP) | 2012-02-21 | — | — | US | disclosed |
| EP-1490044-A4 | COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS | NEUROGEN CORP (US) | 2008-04-16 | — | — | EP | disclosed |
| US-7186734-B2 | Aryl imidazoles and related compounds as C5a receptor modulators | NEUROGEN CORPORATION (US) | 2007-03-06 | — | — | US | disclosed |
| US-7186734-B2 | Aryl imidazoles and related compounds as C5a receptor modulators | NEUROGEN CORPORATION (US) | 2007-03-06 | — | — | US | disclosed |
| US-7186734-B2 | Aryl imidazoles and related compounds as C5a receptor modulators | NEUROGEN CORPORATION (US) | 2007-03-06 | — | — | US | disclosed |
| EP-1186638-B1 | Use of a printing ink, printing method and printed packaging material | TOYO SEIKAN KAISHA LTD (JP) | 2006-06-07 | — | — | EP | disclosed |
| EP-1490044-A1 | COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS | NEUROGEN CORPORATION (US) | 2004-12-29 | — | — | EP | disclosed |
| WO-2003084524-A1 | COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS | NEUROGEN CORPORATION (US) | 2003-10-16 | — | — | WO | disclosed |
| EP-1186638-A1 | Printing ink, printing method and printed packaging material | TOYO SEIKAN KAISHA LIMITED (JP) | 2002-03-13 | — | — | EP | disclosed |